Key Highlights
- 31.5 percent was the September 29, 2026 gain for Iovance Biotherapeutics (NASDAQ:IOVA), which closed at USD 14.45 from USD 10.99 after the company raised its 2026 Revenue guidance.
- USD 410 million to USD 420 million is the new 2026 revenue guidance, up from USD 350 million to USD 370 million, a rise of about USD 55 million at the midpoint by simple arithmetic.
- USD 99.3 million of second quarter product revenue, up from USD 59.95 million a year earlier, underpins the Amtagvi launch at Iovance Biotherapeutics (NASDAQ:IOVA) and its roughly 100 treatment centers.
- 0.56 percent was the October 5, 2026 decline to USD 14.14, so Iovance (NASDAQ:IOVA) has held most of the jump, though third quarter results are due in early November.
The Guidance Raise
On September 29, 2026 Iovance Biotherapeutics (NASDAQ:IOVA) raised its 2026 total revenue guidance to USD 410 million to USD 420 million from USD 350 million to USD 370 million. Published market data show the shares closing at USD 14.45 against USD 10.99 the prior session, a gain of 31.5 percent, on Volume of about 78 million shares versus roughly 12 million on a typical day. The company said Amtagvi, its one-time cell therapy for previously treated advanced melanoma, is now approved in three global markets. It also said its authorized treatment center network has grown to about 100 and should reach at least 110 by year-end 2026. Shares then drifted to USD 14.14 on October 5, down 0.56 percent.
Why Guidance Matters Here
Amtagvi is made from each patient's own tumor-infiltrating lymphocytes, so revenue depends on treatment centers referring patients, the Iovance Cell Therapy Center Manufacturing each dose, and payers reimbursing a high-priced one-time therapy. A raised outlook suggests those steps are moving faster than planned. Second quarter product revenue of USD 99.3 million compared with USD 59.95 million a year earlier. Because the stock had traded near USD 10 to USD 11 for weeks, a guidance increase of about 15 percent at the midpoint, by simple arithmetic on the two ranges, forced a large reassessment of expected sales. On October 5, 2026 the company also updated its corporate presentation for healthcare conferences, which restated manufacturing, reimbursement and regulatory risks.
Risks and What to Watch
Cell therapy launches can stall if manufacturing capacity, referral timing or reimbursement lags, and the presentation itself lists increasing capacity at the Iovance Cell Therapy Center as a risk to commercial launch. A one-day gain of this size can also reverse, and preliminary clinical results may not hold in final analyses. Iovance has a history of sharp swings, including a drop of more than 25 percent after an earlier quarterly miss and restructuring. Investors will watch whether the company hits 110 treatment centers by year-end and the third quarter results, expected in early November 2026, with a specific date not confirmed. The Federal Reserve minutes at 2:00 p.m. ET on October 7 may also move small-cap biotech. Not Investment advice.
Where Things Stand
Iovance Biotherapeutics (NASDAQ:IOVA) jumped 31.5 percent because it raised 2026 revenue guidance to USD 410 million to USD 420 million, not because of the October 5 presentation, which moved the shares only 0.56 percent. The company now has a stronger sales story and a share price well above its September level, but that depends on manufacturing, reimbursement and treatment center growth continuing. Readers should treat the October 5 presentation as a risk disclosure, and the next hard data point is the November report.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...